Trials / Completed
CompletedNCT05516966
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus
A Phase 1, Randomized, Double-Blind, Placebo- and Positive-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to assess the safety and tolerability of multiple subcutaneous injections of HRS9531 in patients with type 2 diabetes mellitus who have suboptimal glycaemic control after conventional lifestyle or metformin intervention.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS9531 | Administrated SC |
| DRUG | Placebo | Administrated SC |
| DRUG | Dulaglutide Injection | Administrated SC |
Timeline
- Start date
- 2022-10-12
- Primary completion
- 2023-05-24
- Completion
- 2023-05-24
- First posted
- 2022-08-26
- Last updated
- 2024-11-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05516966. Inclusion in this directory is not an endorsement.